UF Innovate | Accelerate’s Post

𝐄𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐔𝐧𝐜𝐡𝐚𝐢𝐧𝐞𝐝 𝐋𝐚𝐛𝐬 𝐚𝐬 𝐚 𝐒𝐩𝐨𝐧𝐬𝐨𝐫 𝐟𝐨𝐫 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝟐𝟎𝟐𝟒! We are proud to announce that Unchained Labs, a company dedicated to transforming the landscape of biologics and gene therapy research, has joined Biologics 2024 as a sponsor. Unchained Labs is committed to unleashing innovative, problem-solving products that make a significant impact on the real science researchers do every day. Their approach is not just a business strategy; it's a mantra and a promise to the research community. By offering tools that go beyond the ordinary, Unchained Labs empowers researchers to break free from conventional limitations, facilitating advancements in biologics and gene therapy that were previously unattainable. Their dedication to innovation and quality is a beacon for researchers striving to tackle the most challenging problems in the field. As we gear up for Biologics 2024, our partnership with Unchained Labs underscores the importance of cutting-edge tools and technologies in driving scientific discovery and development. Join us to explore how Unchained Labs' revolutionary products are setting new standards in research and opening doors to new possibilities. View the full agenda: https://hubs.la/Q02lCdPN0 #Biologics24 #OGBiologics #UnchainedLabs #BiologicsResearch #GeneTherapy #Innovation #ScientificDiscovery

𝐄𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐔𝐧𝐜𝐡𝐚𝐢𝐧𝐞𝐝 𝐋𝐚𝐛𝐬 𝐚𝐬 𝐚 𝐒𝐩𝐨𝐧𝐬𝐨𝐫 𝐟𝐨𝐫 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝟐𝟎𝟐𝟒! We are proud to announce that Unchained Labs, a company dedicated to transforming the landscape of biologics and gene therapy research, has joined Biologics 2024 as a sponsor. Unchained Labs is committed to unleashing innovative, problem-solving products that make a significant impact on the real science researchers do every day. Their approach is not just a business strategy; it's a mantra and a promise to the research community. By offering tools that go beyond the ordinary, Unchained Labs empowers researchers to break free from conventional limitations, facilitating advancements in biologics and gene therapy that were previously unattainable. Their dedication to innovation and quality is a beacon for researchers striving to tackle the most challenging problems in the field. As we gear up for Biologics 2024, our partnership with Unchained Labs underscores the importance of cutting-edge tools and technologies in driving scientific discovery and development. Join us to explore how Unchained Labs' revolutionary products are setting new standards in research and opening doors to new possibilities. View the full agenda: https://hubs.la/Q02lC8050 #Biologics24 #OGBiologics #UnchainedLabs #BiologicsResearch #GeneTherapy #Innovation #ScientificDiscovery

What an inspiring journey! Cell & Gene is a New Frontier in medical science.

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Metagenomi finally sets IPO range, as preclinical biotech eyes $87M: Gene editing company Metagenomi has set a price range for its proposed initial public offering, marking a key step for preclinical biotechs after weeks of anticipation on whether the California startup would follow through with a listing. Metagenomi expects net proceeds of about $87 million if it prices at $16 per share, the midpoint of its proposed range disclosed Monday morning in an SEC filing. The biotech will likely go public later this week by selling 6.25 million shares. There’s a chance its proceeds could balloon if the company upsizes before landing on Nasdaq as “MGX,” as CG Oncology, ArriVent BioPharma and Alto Neuroscience did in the past two weeks. The Moderna-allied Metagenomi would be one of the only biotechs to go public in the past two years before it had any therapeutic programs in human testing, and one of the only gene editing startups to do so either. Endpoints News first reported Metagenomi was working with JP Morgan on an IPO last August. Metagenomi likely wouldn’t open the floodgates for preclinical IPOs, which rushed onto the public scene in the heyday of 2020 and 2021 for platform biotechs. No other preclinical biotech has revealed its plans to go public since Metagenomi’s paperwork was disclosed in the first week of January. A Phase II autoimmune cell therapy company, Kyverna Therapeutics, will list later this week. The biotech is still years away from human testing, saying in its S-1 that it’s in the research or lead optimization stage. With the IPO, Metagenomi said it expects to have enough money to keep the lights on into 2027. It had about $292 million in cash, equivalents and marketable securities at the end of last September. About $125 million is earmarked for preclinical studies, another $85 million for IND-enabling studies and at least two IND filings, $75 million for platform discovery and other early-stage research, as well as $50 million for manufacturing work, Metagenomi outlined in its updated IPO paperwork. Founded by CEO Brian Thomas and UC Berkeley professor Jillian Banfield in 2016, Metagenomi has since explored a wealth of potential gene editing tools. The company said it has identified more than 20,000 new gene editing systems after pouring through 322 million CRISPR-associated proteins and 1.75 million CRISPRs, per its S-1. Over the years, Metagenomi has reeled in more than $400 million on the private side from Bayer’s VC arm, Moderna, RA Capital, Humboldt Fund and Novo Holdings, among others. It’s also inked partnerships with Moderna, Ionis and Affini-T, which is working with Metagenomi on ex vivo cell therapies for immuno-oncology and autoimmune programs. Its most advanced programs are in hemophilia A, primary hyperoxaluria type 1,… #lucidquest #genetherapy #celltherapy

[Repost] At the end of 2023, SEQENS acquired CELLforCURE by Seqens from NOVARTIS.   With this acquisition, the Group aims to: 👉 Capitalize on a state-of-the-art infrastructure and recognized know-how, 👉 Bring its expertise of a world leader CDMO, 👉 Integrate CELLforCURE to a global network with substantial investment capacity to ensure rapid development and sustainability.     🚀 Want to follow this exciting adventure and learn more about future therapies? Follow CELLforCURE by Seqens! #biotherapies #futuretherapies #ourscienceforyourfuture

Gene&Cell Therapy >> Metagenomi finally sets IPO range, as preclinical biotech eyes $87M: Gene editing company Metagenomi has set a price range for its proposed initial public offering, marking a key step for preclinical biotechs after weeks of anticipation on whether the California startup would follow through with a listing. Metagenomi expects net proceeds of about $87 million if it prices at $16 per share, the midpoint of its proposed range disclosed Monday morning in an SEC filing. The biotech will likely go public later this week by selling 6.25 million shares. There’s a chance its proceeds could balloon if the company upsizes before landing on Nasdaq as “MGX,” as CG Oncology, ArriVent BioPharma and Alto Neuroscience did in the past two weeks. The Moderna-allied Metagenomi would be one of the only biotechs to go public in the past two years before it had any therapeutic programs in human testing, and one of the only gene editing startups to do so either. Endpoints News first reported Metagenomi was working with JP Morgan on an IPO last August. Metagenomi likely wouldn’t open the floodgates for preclinical IPOs, which rushed onto the public scene in the heyday of 2020 and 2021 for platform biotechs. No other preclinical biotech has revealed its plans to go public since Metagenomi’s paperwork was disclosed in the first week of January. A Phase II autoimmune cell therapy company, Kyverna Therapeutics, will list later this week. The biotech is still years away from human testing, saying in its S-1 that it’s in the research or lead optimization stage. With the IPO, Metagenomi said it expects to have enough money to keep the lights on into 2027. It had about $292 million in cash, equivalents and marketable securities at the end of last September. About $125 million is earmarked for preclinical studies, another $85 million for IND-enabling studies and at least two IND filings, $75 million for platform discovery and other early-stage research, as well as $50 million for manufacturing work, Metagenomi outlined in its updated IPO paperwork. Founded by CEO Brian Thomas and UC Berkeley professor Jillian Banfield in 2016, Metagenomi has since explored a wealth of potential gene editing tools. The company said it has identified more than 20,000 new gene editing systems after pouring through 322 million CRISPR-associated proteins and 1.75 million CRISPRs, per its S-1. Over the years, Metagenomi has reeled in more than $400 million on the private side from Bayer’s VC arm, Moderna, RA Capital, Humboldt Fund and Novo Holdings, among others. It’s also inked partnerships with Moderna, Ionis and Affini-T, which is working with Metagenomi on ex vivo cell therapies for immuno-oncology and autoimmune programs. Its most advanced programs are in hemophilia A, primary hyperoxaluria type 1, transthyretin amyloidosis and an immuno-oncology… #lucidquest #genetherapy #celltherapy

As companies step into the advanced therapies arena, understanding and managing risks is paramount. The recent growth of the diverse cell, gene, and RNA therapeutics industries has led to manufacturing growing pains and shake-ups on both the innovator and CDMO sides. And not surprisingly, these concerns center around the topic of risk. What does it mean for a biotech and CDMO to share risk in the ATMP space? Is it just focused on the financial? Or the science? Or something else? A range of partnership models are emerging in the cell and gene therapy sector. Biotechs and CDMOs are collaboratively evolving; at times, CDMOs lead the process development and manufacturing, while in hybrid models, biotechs actively invest in early-stage development before transitioning to CDMOs. These models are crucial for industry growth. More often, simultaneous collaboration is recommended, involving CDMOs very early in process development to address tech transfer challenges efficiently - they are essentially learning together how to characterize and scale those processes. Read more from Cell & Gene's series on advanced therapies and outsourcing: https://lnkd.in/efwF5Fws #cellandgenetherapy #outsourcing #partnershipsuccess

🌟 Big News in the Biotech World! 🌟 Ajinomoto Co., Inc. has just announced a groundbreaking acquisition of Forge Biologics for a whopping $620 million! 💰 This move marks a significant expansion in the gene therapy manufacturing sector, showcasing Ajinomoto's commitment to innovation and healthcare advancement. 🧬🔬 Founded in 2020, Forge Biologics has rapidly grown into a leader in gene therapy development and manufacturing. Their state-of-the-art facility in Columbus, Ohio, and their talented team are set to join forces with Ajinomoto, bringing new capabilities and expanding global outreach. 🌍 This acquisition is not just a business move; it's a step towards enabling access to life-changing gene therapies for patients worldwide. 🌏💉 The combined expertise of Ajinomoto and Forge Biologics promises to accelerate the development of transformative medicines, making a real difference in the lives of many. 🙌 👉For more details on this exciting development, check out the full article here: https://zurl.co/lkYo 👉Listen to Tim Miller, CEO of Forge Biologics on the 614Startups Podcast here: https://zurl.co/P2Rx #Biotech #GeneTherapy #Innovation #Healthcare #Ajinomoto #ForgeBiologics #MergersAndAcquisitions

bluebird is doing great science and commercializing breakthrough therapeutics. Why are they having trouble with funding? bluebird announced another public stock offering, diluting current shareholders and seeking to raise $150 million. Additionally they're seeking to sell "certain trade accounts receivable" - future sales of their three commercialized gene therapies. The short answer is that the market is finding it tough to swallow the price tag for the therapeutics. There are efficiencies that must be uncovered for bluebird to unlock their potential, in the supply chain and manufacturing areas most significantly. https://lnkd.in/gnymysQx

Thoughts on this? >> Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #biotech #pharma #pharmaceutical